FDA Sets December 2026 Decision Date for Hansa Biopharma's Kidney Transplant Drug

Event summary

  • FDA assigned a PDUFA action date of December 19, 2026 for Hansa Biopharma's imlifidase BLA.
  • Imlifidase targets highly sensitized kidney transplant patients, a 10–15% underserved group.
  • Drug is conditionally approved in Europe, UK, Australia, and Switzerland under IDEFIRIX.
  • Hansa aims to address prolonged waiting times and dialysis dependence for these patients.

The big picture

Hansa Biopharma's imlifidase represents a potential breakthrough for highly sensitized kidney transplant patients, a group with limited treatment options. The FDA's PDUFA date sets a critical milestone for the drug's U.S. approval, which could significantly expand its market reach. The strategic focus on this underserved patient population aligns with broader industry trends toward precision medicine and addressing unmet medical needs.

What we're watching

Regulatory Approval
Whether the FDA will approve imlifidase by the December 2026 deadline, given its conditional approval status in other regions.
Market Expansion
The pace at which Hansa can expand imlifidase's reach beyond Europe and into the U.S. market.
Competitive Positioning
How IDEFIRIX's established presence in Europe will influence imlifidase's adoption in the U.S.